Walleye Capital’s BridgeBio Pharma BBIO Stock Holding History

Walleye Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$432K	Buy	5,800 +2,400	+71%	+$168K	﹤0.01%	2875
2026 Q1	$252K	Sell	3,400 -12,800	-79%	-$928K	﹤0.01%	3187
2025 Q4	$1.24M	Buy	16,200 +6,300	+64%	+$414K	﹤0.01%	2261
2025 Q3	$514K	Sell	9,900 -7,600	-43%	-$371K	﹤0.01%	2584
2025 Q2	$756K	Buy	17,500 +15,400	+733%	+$560K	﹤0.01%	2282
2025 Q1	$72.6K	Sell	2,100 -5,300	-72%	-$179K	﹤0.01%	3735
2024 Q4	$203K	Buy	+7,400	New	+$191K	﹤0.01%	3751
2024 Q3	–	Sell	-3,600	Closed	-$91.2K	–	5294
2024 Q2	$91.2K	Buy	3,600 +300	+9%	+$8.2K	﹤0.01%	4762
2024 Q1	$102K	Buy	+3,300	New	+$112K	﹤0.01%	4385
2023 Q4	–	Sell	-2,500	Closed	-$65.9K	–	4934
2023 Q3	$65.9K	Sell	2,500 -69,300	-97%	-$1.97M	﹤0.01%	4110
2023 Q2	$1.23M	Buy	71,800 +60,800	+553%	+$915K	﹤0.01%	1671
2023 Q1	$182K	Buy	+11,000	New	+$128K	﹤0.01%	2540

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Walleye Capital's BBIO Position: Q2 2026 in Review

Walleye Capital reduced its BridgeBio Pharma (BBIO) stake by 99% in Q2 2026, selling an estimated $15.9M and leaving 1,535 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #3830.

Walleye Capital first reported a position in BBIO in Q1 2021 and has held it in 13 quarters since. The position peaked at $17M in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Walleye Capital held 1,535 shares of BridgeBio Pharma worth $114K as of Q2 2026.
Walleye Capital sold 227,058 BridgeBio Pharma shares in Q2 2026, an estimated $15.9M.
BridgeBio Pharma made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3830 holding.
Walleye Capital first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 13 quarters since.
Walleye Capital's BridgeBio Pharma position peaked at $17M in Q1 2026.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.